Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-07), Boston Scientific's 12-1 Month Momentum % is N/A%.
The industry rank for Boston Scientific's 12-1 Month Momentum % or its related term are showing as below:
XSWX:BSX's 12-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -17.4 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Boston Scientific (XSWX:BSX) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Boston Scientific 12-1 Month Momentum % Related Terms
Boston Scientific (XSWX:BSX) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific (XSWX:BSX) has a 12-1 Month Momentum % of N/A% as of Sep. 07, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Boston Scientific and its competitors. According to the industry distribution chart, Boston Scientific ranks #713 out of 824 companies in the Medical Devices & Instruments industry, placing it in the top 86.5%.
Is Boston Scientific's 12-1 Month Momentum % too high?
Boston Scientific's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Boston Scientific ranks #713 out of 824 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boston Scientific has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's 12-1 Month Momentum % compare to EW and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #713 out of 824 companies for 12-1 Month Momentum %. This places Boston Scientific in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Boston Scientific and its competitors. Boston Scientific's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Boston Scientific (XSWX:BSX) has a current 12-1 Month Momentum % of N/A%. The stock's GF Value™ is CHF86.18, compared to a current price of CHF38.44 — trading 55.4% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Boston Scientific's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Boston Scientific (XSWX:BSX), the current 12-1 Month Momentum % is N/A% as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (XSWX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of CHF38.44 is trading 55.4% below its estimated GF Value™ of CHF86.18.
Key valuation signals for XSWX:BSX:
12-1 Month Momentum %: N/A%
GF Value™: CHF86.18 vs. price of CHF38.44 (55.4% below fair value)
No single metric tells the full story. See the XSWX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
77GF Score
Get the complete analysis for XSWX:BSX
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSX has been successfully added to your 
